Repligen (RGEN) Financial Analysis & Valuation | Quarter Chart
Repligen (RGEN)
RGENPrice: $113.37
Fair Value: 🔒
🔒score
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography r... more
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in b... more
Description
Shares
| Market Cap | $6.39B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | US | CEO | Olivier Loeillot |
| IPO Date | 1986-04-29 | CAGR | 0.15% |
| Employees | 1,778 | Website | www.repligen.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 2.78% | Total Yield | 2.78% |
RGEN chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.59B | P/E Ratio | 124.58 |
| Forward P/E | 45.08 | PEG Ratio | 2.64 |
| P/S Ratio | 4.83 | P/B Ratio | — |
| P/CF Ratio | 25.85 | P/FCF Ratio | 32.93 |
| EPS | $0.91 | EPS Growth 1Y | -172.82% |
| EPS Growth 3Y | -98.96% | EPS Growth 5Y | -96.34% |
| Revenue Growth 1Y | 14.91% | Gross Margin | 0.11% |
| Operating Margin | 0% | Profit Margin | 0% |
| ROE | — | ROA | — |
| ROCE | 0% | Current Ratio | — |
| Quick Ratio | — | Cash Ratio | — |
| Debt/Equity | — | Interest Coverage | -0.08 |
| Altman Z Score | — | Piotroski Score | 6 |